ReviewClinical and experimental gastroenterology2014
The p53/microRNA connection in gastrointestinal cancer.
Review in Clinical and experimental gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 50 citations in OpenAlex.
- Serum microRNA Profiles Reflect Differentiation Status and Age in Early Gastric Cancer.Biomolecules · 2026Article
- Photodynamic Therapy and Dietary Antioxidants: A Dual Strategy for Genome Stability and DNA Damage Repair.Cancer medicine · 2025Review
- Huashi Jiedu Decoction Enhances 5-Fluorouracil Efficacy in Gastric Cancer via miRNA-21-3p/p53 Pathway.Drug design, development and therapy · 2025Article
- P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.Oncology reports · 2023Article
- The Clinical Significance of MicroRNAs in Colorectal Cancer Signaling Pathways: A Review.Global medical genetics · 2023Review
- GraphTar: applying word2vec and graph neural networks to miRNA target prediction.BMC bioinformatics · 2023Article
- Review
- Upregulated miRNAs on theFrontiers in genetics · 2022Article
- A systematic approach introduced novel targets in rectal cancer by considering miRNA/mRNA interactions in response to radiotherapy.Cancer biomarkers : section A of Disease markers · 2022Article
- MicroRNA-106a regulates autophagy-related cell death and EMT by targeting TP53INP1 in lung cancer with bone metastasis.Cell death & disease · 2021Article
- Identification of colorectal cancer associated biomarkers: an integrated analysis of miRNA expression.Aging · 2021Article
- NEM-Tar: A Probabilistic Graphical Model for Cancer Regulatory Network Inference and Prioritization of Potential Therapeutic Targets From Multi-Omics Data.Frontiers in genetics · 2021Article
- MicroRNA Expression and Correlation with mRNA Levels of Colorectal Cancer-Related Genes.Journal of gastrointestinal cancer · 2020Article
- Angioregulatory microRNAs in Colorectal Cancer.Cancers · 2019Review
- Epigenetic alterations in TRAMP mice: epigenome DNA methylation profiling using MeDIP-seq.Cell & bioscience · 2018Article
- Prognostic role of HSPs in human gastrointestinal cancer: a systematic review and meta-analysis.OncoTargets and therapy · 2018Article
- Wild-type and mutant p53 differentially modulate miR-124/iASPP feedback following pohotodynamic therapy in human colon cancer cell line.Cell death & disease · 2017Article
- CDK1 interacts with iASPP to regulate colorectal cancer cell proliferation through p53 pathway.Oncotarget · 2017Article
- Circular RNA participates in the carcinogenesis and the malignant behavior of cancer.RNA biology · 2017Review
- Circulating exosomes and exosomal microRNAs as biomarkers in gastrointestinal cancer.Cancer gene therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protein encoded by the TP53 gene is one of the most important suppressors of tumor formation, which is also frequently inactivated in gastrointestinal cancer. MicroRNAs (miRNAs) are small noncoding RNAs that inhibit translation and/or promote degradation of their target messenger RNAs. In recent years, several miRNAs have been identified as mediators and regulators of p53's tumor suppressing functions. p53 induces expression and/or maturation of several miRNAs, which leads to the repression of critical effector proteins. Furthermore, certain miRNAs regulate the expression and activity of p53 through direct repression of p53 or its regulators. Experimental findings indicate that miRNAs are important components of the p53 network. In addition, the frequent genetic and epigenetic alterations of p53-regulated miRNAs in tumors indicate that they play an important role in cancer initiation and/or progression. Therefore, p53-regulated miRNAs may represent attractive diagnostic and/or prognostic biomarkers. Moreover, restoration of p53-induced miRNAs results in suppression of tumor growth and metastasis in mouse models of cancer. Thus, miRNA-based therapeutics may represent a feasible strategy for future cancer treatment. Here we summarize the current published state-of-the-art on the role of the p53-miRNA connection in gastrointestinal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.